Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24838080 | 0.94 | HRH3 (0.37) | HRH3CHRM1CYP3A4CYP2C19POLB | |
| SCHEMBL25605546 | 0.94 | KDM4E (0.40) | HRH3CYP3A4CYP2C19POLBKDM4E | |
| SCHEMBL25600462 | 0.94 | HRH3 (0.38) | HRH3CHRM1CYP3A4CYP2C19POLB | |
| SCHEMBL25605552 | 0.94 | KDM4E (0.40) | HRH3CYP3A4CYP2C19POLBKDM4E | |
| SCHEMBL24838472 | 0.92 | OPRL1 (0.38) | HRH3POLBKDM4E | |
| SCHEMBL24838158 | 0.92 | OPRL1 (0.38) | HRH3POLBKDM4E | |
| SCHEMBL25605342 | 0.90 | HRH3 (0.36) | HRH3CHRM1CYP3A4CYP2C19POLB | |
| SCHEMBL24838021 | 0.89 | ALDH1A1 (0.42) | HRH3CYP3A4CYP2C19KDM4EMEN1 | |
| SCHEMBL25600461 | 0.89 | ALDH1A1 (0.42) | HRH3CYP3A4CYP2C19KDM4EMEN1 | |
| SCHEMBL25600538 | 0.87 | HRH3 (0.34) | HRH3CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885CHRM1 4634/4885CYP3A4 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.